Clinical trial
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid…
NCT00387504 · California Cancer Consortium, Other · Completed
Key facts
| NCT number | NCT00387504 |
|---|---|
| Title | Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors |
| Official title | Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Malignant Solid Tumors |
| Lead sponsor | California Cancer Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | fenretinide, pharmacological study |
| Enrollment | 21 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2013 |
| First posted | Oct 13, 2006 |
| Last update posted | Sep 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: